Russian Journal of Allergy最新文献

{"title":"SENSITIZATION TO CHICKEN EGG PROTEIN IN CHILDREN WITH ALLERGIC PATHOLOGY AT DIFFERENT AGE PERIODS","authors":"M. Snovskaya, E. Semikina, S. Makarova, O. Ereshko, D. Yasakov, A. Galimova","doi":"10.36691/rja1565","DOIUrl":"https://doi.org/10.36691/rja1565","url":null,"abstract":"Relevance: world studies showed that egg allergy is one of the main causes of IgE-mediated food allergies in children. The aim of our study was analyzing the frequency and rate of sensitization to white egg of the Russian population's children, depending on the gender and age. Materials and methods: allergen-specific IgE levels were measured in children with food allergy (4981 patients aged 6 months-18 years). The frequency and degree of sensitization in various age groups were analyzed. Results: 29.5% of children had an anti-egg IgE antibodies. Among all positive responses, the low (31.6%, IgE=0.35-0.69 kU/l) and moderate (40.2%, IgE=0.70-3.5 kU/l) sensitization were most common. An extremely high level of anti-egg antibodies (IgE50.0 kU/l) was observed in 6.2% of patients. The highest frequency of sensitization was revealed in patients under the age of one year (39%). Decreasing of the positive responses frequency was noted in patients of older age groups. The dependence of the sensitization frequencies on sex was found in children over 12 years old. Frequencies of egg sensitization in girls aged 12-14 and 14-18 were statistically significantly lower compared to those in boys of the same age. The dependence of the response severity on the patient's age was also noted: a decrease in the frequency of highly positive responses and an increase in proportion of patients with medium or low IgE levels in older children were found. There was a decrease in the severity of the IgE-response by the age of 12 years in girls and by the age of 14 years in boys. Conclusion: the frequency and severity of positive IgE-responses to white egg allergens extract is the highest in children of the first year of life. These parameters decrease in older children, After 12 years of age the response severity and frequency are associated with the patient's gender. The marked tendency towards a decrease in the number of patients who have a positive response to a white egg allergens extract and the degree of its severity by adolescence may be evidence of the development of tolerance to this food product with the age.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"21 7","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133719912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The significance of component-resolved allergy diagnostics in atopic dermatitis patients when prescribing allergen-specific immunotherapy","authors":"O. Elisyutina, E. Fedenko, E. V. Smolnikov, A. Litovkina, O. Shtyrbul","doi":"10.36691/rja1588","DOIUrl":"https://doi.org/10.36691/rja1588","url":null,"abstract":"The paper presents two clinical cases of patients with severe atopic dermatitis (AD) with polyvalent sensitization: in an adult patient and in a child. Standard topical and systemic therapy proved to be an insufficiently effective strategy in these patients. Both patients underwent component-resolved allergy diagnostics, which made it possible to identify the causally significant components of allergens, sensitization to which affects the course of AD. On the basis of the survey, indications for ASIT with causally significant allergens were determined. The performed treatment made it possible to achieve non-drug remission not only of AD, but also of concomitant respiratory allergic diseases. The cases presented by us demonstrate the efficacy and safety of ASIT in patients with proven sensitization to causally significant allergens based on component allergy diagnostics.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"201 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122581558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of anti-IL4R,13 therapy in patients with severe bronchial asthma with concomitant chronic inflammatory nasal diseases","authors":"V. Naumova, D. Kiseleva, Evgeny K. Beltyukov","doi":"10.36691/rja1580","DOIUrl":"https://doi.org/10.36691/rja1580","url":null,"abstract":"BACKGROUND: T2-inflammation underlies bronchial asthma and inflammatory nasal diseases, supporting concept of an \"united airway disease\". Dupilumab, by blocking interleukin 4 and 13 receptor, can improve clinical and functional parameters and life quality of comorbid patients with T2 diseases. \u0000AIM: to evaluate efficacy of anti-IL4R,13 therapy in patients with severe asthma with chronic inflammatory nasal diseases in real clinical practice. \u0000MATERIALS AND METHODS: The study of dupilumab efficacy was conducted by method of related populations comparison based on regional register of patients with severe asthma (SA) and concomitant chronic inflammatory nasal diseases (CIND). Asthma control achievement and decrease in rate of patients with uncontrolled asthma were assessed as primary endpoint. The need for bronchodilators and systemic glucocorticosteroids, the number of asthma exacerbations, emergency calls and hospitalizations, AQLQ scores, level of peripheral blood eosinophils, and respiratory function were also assessed. Nasal symptoms were assessed using SNOT22 and VAS. A subgroup analysis of ACT scores was performed depending on CIND phenotypes. \u0000RESULTS: During 12 months of dupilumab therapy, ACT increased from 11 (Q1-Q3: 7-13) to 20 (Q1-Q3: 18-24) points (p0.001). The rate of patients with uncontrolled asthma decreased from 100% to 42.1% (p0.001). Need for bronchodilators decreased from 17.5 doses per week (Q1-Q3: 5.8-24.5) to 1.0 (Q1-Q3: 0.0-2.2) (p0.001). Before dupilumab therapy, 68.5% of patients took systemic corticosteroids, after 12 months - 10.5% of patients (p0.001). The number of asthma exacerbations decreased from 2.191.83 (95% CI 1.28-3.11) to 0.220.55 (0.05-0.49) (p0.001) and hospitalizations from 1.001.27 (95% CI 0.37-1.63) to 0.170.51 (95% CI 0.09-0.42) (p0.001). AQLQ scores increased from 2.91 (Q1-Q3: 2.43-3.86) to 5.89 points (Q1-Q3: 4.70-6.58) (p0.001). FEV1 increased from 55.38%16.66 (95% CI 47.10-63.67) to 81.5%19.14 (95% CI 71.98-91.02) (p0.001). SNOT22 scores decreased from 4729 (95% CI 34-61) to 2518 (95% CI 17-34) points (p0.001), VAS - from 72 (95 %CI 6-8) to 42 (95%CI 3-5) (p0.001). \u0000CONCLUSIONS: Dupilumab improved asthma and nasal symptoms control, improved quality of life and respiratory function, reduce asthma exacerbations and hospitalizations. Patients with severe asthma and comorbid allergic rhinitis and chronic rhinosinusitis with polyps responded better to dupilumab therapy than patients with chronic rhinosinusitis without polyps.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117338645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and implementation in outpatient practice of an electronic computer program \"Diagnostics of bronchial asthma in children\"","authors":"N. Samigullina","doi":"10.36691/rja1543","DOIUrl":"https://doi.org/10.36691/rja1543","url":null,"abstract":"Background. Currently, the criteria for the differential diagnosis of bronchial asthma and a number of respiratory diseases in children, accompanied by bronchial obstruction syndrome, remain insufficiently effective. At the same time, timely administration of anti-inflammatory therapy is important.Aim: Development and introduction into the practice of outpatient medical organizations of a computer program for the timely diagnosis of asthma in children and the appointment of basic therapy.Materials and methods. A comparative comprehensive analysis of risk factors for the formation of the disease was carried out in 170 children with bronchial asthma and 170 clinically healthy children who had episodes of bronchial obstruction at an early age. The program was tested in the observation of 72 children with episodes of bronchial obstruction.Three years after the introduction of the program into practice, an analysis was made of the diagnosis of bronchial asthma in 92 children.Results. 62 most significant signs (predictors of the disease) were established, which formed the basis of the developed computer program \"Diagnostics of bronchial asthma in children\". Approbation of the program in clinical conditions showed a high consistency of the result with the conclusion of an allergist-immunologist. Statistical analysis showed that the sensitivity of the method was 88.2%, the specificity was 94.1% (p0.05). The program was introduced into the practice of outpatient medical organizations.Three years after the introduction of the program into the practice of outpatient institutions, the number of patients diagnosed with asthma during the year increased by 3 times.Conclusion. The data obtained determine the possibility of using the proposed computer program as a tool for the timely diagnosis of BA in children.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131040536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and predictors of rapid response to omalizumab therapy in patients with seasonal allergic rhinitis: a cohort study.","authors":"D. Fomina, O.U. Mukhina, E. Bobrikova, M. Lebedkina, A. Chernov, M. Lysenko","doi":"10.36691/rja1564","DOIUrl":"https://doi.org/10.36691/rja1564","url":null,"abstract":"BACKGROUND: The availability of anti-IgE therapy for allergic rhinitis (AR) has actualized the need to develop variants of this treatment according to predictors of rapid response and the tactics of treatment initiation. \u0000AIMS: To study efficacy and predictors of response to omalizumab in patients with seasonal AR (SAR). \u0000MATERIALS AND METHODS: Patients with moderate or severe SAR with insufficient effectiveness of traditional treatment for at least 3 months in previous pollen season or with no effect of therapy in current season were included. The decision to prescribe omalizumab was made based on the visual analog scale (VAS) in the previous or current season. Dosage and frequency of administration (every 2 or 4 weeks) were determined according to the table values due to the instructions. The patients were observed for 2 months. At follow-up visits (1 and 2 months later), AR symptom control was assessed using VAS and TNSS. Therapy was considered effective when the VAS remained 30 or decreased 30 after 4 and 8 weeks from the start of therapy, depending on the initiation period. \u0000RESULTS: The study enrolled 30 patients with AR history of 14 years, sensitization to 2 or more groups of allergens in 19 (63,3%) cases, bronchial asthma (BA) in 18 (60%). In 6 patients (20%) omalizumab was initiated before the pollen season, in 24 patients (80%) during the season. After 4 weeks, control of AR manifestations was achieved in 23 (77%) patients, and by week 8, 100% of patients with AR had fully responded to therapy. In patients, the severity of AR symptoms on the VAS/ TNSS scales decreased by 2.7 and 4.7 times, respectively, by 4 weeks of follow-up. The proportion of patients with a slow response by week 4 of therapy was 23%. BMI (lower in the \"slow\" response group) and history of BA (2.6 times longer in the \"slow\" responders) were associated with the achievement of this outcome. No adverse events were recorded. \u0000CONCLUSIONS: Omalizumab in patients with SAR allows to achieve control of manifestations of the disease already after 4 weeks of therapy with its maintenance in follow-up. Predictors of rapid response have been revealed, but their clinical significance requires further study.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121120561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogenetic mechanisms of transcutaneous sensitization to food allergens in inherited epidermolysis bullosa.","authors":"A. Galimova","doi":"10.36691/rja1568","DOIUrl":"https://doi.org/10.36691/rja1568","url":null,"abstract":"Congenital epidermolysis bullosa is a various group of inherited dermatoses resulting from a pathogenic variant of the genome encoding proteins of the dermo-epidermal junction. This disease is characterized by an early onset, continuous course with frequent exacerbations. Epidermolysis bullosa is clinically and genetically heterogeneous, includes phenotypes with different severity levels and is characterized by changes in 29 different genes. Classical forms of epidermolysis bullosa are divided into four main types depending on the level of bubble formation in the basement membrane zone. One of the most common symptoms in all subtypes of epidermolysis bullosa, as well as significantly reducing the quality of life, is itching. It occurs in areas with blisters or wounds or manifests as a generalized phenomenon, thus affecting both intact skin and healing wounds. The mechanisms of itching in epidermolysis bullosa have not been fully studied. It is likely that skin inflammation secondary to a violation of the skin barrier, cascades of wound healing and unregulated activation of epidermis-sensitive nerve endings are involved in its pathophysiology at the molecular and cellular level. Understanding the causes of these mechanisms is crucial for developing optimal treatment tactics for children with epidermolysis bullosa and improving their quality of life. This review summarizes updated data on clinical and genetic aspects of congenital epidermolysis bullosa.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131552495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of chronic inducible urticaria in Moscow.","authors":"Daria Fonina, S. Serdotetskova, N. Maltseva, I. Danilycheva, M. Lebedkina, V. Mikhailova, Elena V. Kovalkova, A. Karaulov, M. Lysenko","doi":"10.36691/rja1573","DOIUrl":"https://doi.org/10.36691/rja1573","url":null,"abstract":"Background: Chronic inducible urticaria (CIndU) is the group of diseases characterized by the development of wheals, angioedema or both in response to specific triggers. According to global scientific international literature the occurrence of CIndU is 0,5% in general population and about 20-30% in all chronic urticarias. \u0000Aim: There are no statistical data of the prevalence of CIndU in Russian Federation. The aim of this research is evaluation of the epidemiology of chronic inducted urticarias. \u0000Materials and Methods: This analysis based on counts of unique cases of access to medical care in adults due to this pathology in digital EMIAS platform (inpatient and outpatient) in Moscow between 2017 and 2021, including key words search. \u0000Results: indicated that the prevalence of CIndU in Moscow is correlating with published global epidemiological data, its rates are high and tends to increase as in global practice. Limitations of this research are the lack of ubiquitous implementation of standard protocols of provocation testing in outpatient, the low percent of using validated questionnaires and systematic management of patients with CIndU. \u0000Conclusions: Further studies dedicated to this topic are a great unmet need in order to answer a wide spectrum of questions including the diagnosis process and evaluation of the the severity of CIndU, comorbid conditions and optomisation of the treatment process.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130388979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular allergology place in allergen-specific immunotherapy","authors":"D. Timoshenko, K. Pavlova, O. Kurbacheva, N. Ilina","doi":"10.36691/rja1572","DOIUrl":"https://doi.org/10.36691/rja1572","url":null,"abstract":"Laboratory methods of allergy diagnosis are an essential tool in the allergist daily practice. Molecular allergodiagnostics is an advanced examination method that allows detecting the patient individual allergocomponents sensitization. The risk prediction of the severe allergic reactions is the main area of its application, as well as the personalized dietary recommendations creation for food allergy patients. In the determining the appointment of allergen immunotherapy indications clinical and anamnesis data are fundamental, supplemented by the results of traditional methods of allergy examination (skin prick tests or the specific IgE level to whole allergens). The widespread use of such resource-intensive examination as molecular allergodiagnostics for all patients is unjustified before the prescribing allergen immunotherapy. In addition, decisions on the allergen immunotherapy continue or the termination cannot be made based on the change data in the level of clinically relevant specific IgE. At the same time, its use as a third-line diagnostic method can help in solving difficult clinical tasks related to the identification of a causally significant allergen in patients with respiratory allergy symptoms during the seasons of simultaneous dusting of several plants, as well as differentiate the true from the cross-sensitization in polysensitized patients. The molecular allergodiagnostics use will be mandatory in the case of the recombinant therapeutic allergen prescribing, due to the need for a personalized choice of the drug.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117014138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"THE USE OF CETIRIZINE AND LEVOCETIRIZINE IN PATIENTS WITH CHRONIC URTICARIA AND OTHER ALLERGIC DERMATOSES: ISSUES OF DOSAGE INCREASING AND LONG-TERM USE \u0000RESOLUTION OF THE ADVISORY BOARD","authors":"E. Fedenko","doi":"10.36691/rja1574","DOIUrl":"https://doi.org/10.36691/rja1574","url":null,"abstract":"The article reflects the main issues discussed at the Advisory board with the participation of leading dermatovenereologists, allergists and immunologists. The Advisory board has become a platform for discussing the accumulated clinical and organizational problems in the field of managing patients with chronic urticaria and other allergic dermatoses. The Board also discussed the possibility of long-term use of cetirizine and levocetirizine and the use of high doses of these drugs in clinical practice. The subject of discussion was the question of the algorithm for escalation and subsequent de-escalation of the dose of non-sedating H1 antihistamines. Based on the results of the discussion, an algorithm for escalation and de-escalation of doses of antihistamines was created, which can be recommended for use in clinical practice.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132296871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of titanium-coated pacemaker allergy in a 14-year-old patient","authors":"N. Esakova, S. Termosesov, M. Shkolnikova, A. Pampura","doi":"10.36691/rja1567","DOIUrl":"https://doi.org/10.36691/rja1567","url":null,"abstract":"The low informative value of the allergy testing to titanium makes it difficult to diagnose allergy to this component. The present paper describes a case report of an allergy to a titanium-coated pacemaker implanted into a 14-year-old patient. This is the first time eosinophil cationic protein and tryptase to be detected at the inflammation site while making diagnosis of allergy to titanium-coated pacemaker. The reimplantation of a gold-coated pacemaker prevents recurrence of inflammatory changes in the area of pacemaker insertion and infectious complications.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122637203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}